Thermo Fisher licenses biomarker assays to Alere
Life sciences equipment supplier Thermo Fisher Scientific Inc. today announced that it has signed a license agreement with Alere Inc. to add its BRAHMS biomarker assays to Alere’s point-of-care Triage platform.
Waltham-based Thermo Fisher said that the biomarkers that will be available on the Triage system include the BRAHMS Procalcitonin (PCT) test for early detection of sepsis in critically ill patients. Severe sepsis is a life-threatening blood disease that affects 750,000 hospital patients in the U.S. each year, according to Thermo Fisher. Alere will also utilize BRAHMS Copeptin, MR-proADM and MR-proANP, which are novel biomarkers used to diagnose patients who experience symptoms such as chest pains or shortness of breath and seek treatment in a hospital emergency room.